An oral inhibitor of Bruton’s tyrosine kinase (BTK) together with very low-dose prednisone induces control of disease activity in patients with pemphigus at 12 weeks. This was the shown in the phase 2 Believe-PV proof of concept study . The current standard of care is high-dose corticosteroids with prednisone-equivalent doses of ≥1 mg/kg with high toxicity and/or rituximab plus moderate-to-high initial doses of corticosteroids (≥0.5-1mg/kg).
“Despite the recent FDA approval of rituximab for moderate-to-severe pemphigus, there remains an unmet need for a quick-acting, steroid-sparing, anti-inflammatory treatment for this rare disease,” said Prof. Dedee Murrell (University of New South Wales, Australia). BTK inhibition interrupts multiple signalling pathways in immune cells, but not in T cells. In this way, B cell function can be impaired without reducing B cells directly. The agent proved also to be effective in naturally occurring pemphigus in dogs, eve...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma Next Article
Increased cancer risk for patients with keloids »
Table of Contents: AAD 2019
Atopic Dermatitis: Many New Therapies in the Pipeline
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
What's New and Hot in Acne
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.